The Latest Breaking News from Moderna

Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus.

Here's a roundup of top developments in the biotech space over the last 24 hours:

The percentage of people with antibodies increased from 34 percent in December to roughly 58 percent in February, the CDC said.

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The mRNA vaccines developed against COVID-19 owe a lot to the work of Robert Langer, a pioneer in the delivery of mRNA. Langer, who is the Massachusetts Institute of Technology David H. Koch Institute Professor and director of the Langer Lab, helped lay the foundation for the underlying delivery mechanism…

After two years at the front of the line for COVID-19 vaccines and treatments, the U.S. could soon have to begin taking a number

Poland can compromise with Moderna Inc (NASDAQ:MRNA) on increasing the flexibility of COVID-19 vaccine contracts, Reuters reported citing the health minister, striking an upbeat tone after initial talks with the company. Poland has said it will not take or pay for more doses of the COVID-19 vaccine under the European Union's supply contract.  Reuters…

Shares of vaccine companies, including Moderna Inc (NASDAQ: MRNA), are trading higher amid COVID-19 concerns due to rising cases in China.

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.